vs
Amphastar Pharmaceuticals, Inc.（AMPH）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是RESOURCES CONNECTION, INC.的1.6倍（$183.1M vs $117.7M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -10.8%，领先24.1%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -19.2%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $15.6M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -11.8%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
AMPH vs RGP — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $117.7M |
| 净利润 | $24.4M | $-12.7M |
| 毛利率 | 46.8% | 37.1% |
| 营业利润率 | 19.4% | -10.3% |
| 净利率 | 13.3% | -10.8% |
| 营收同比 | -1.8% | -19.2% |
| 净利润同比 | -35.7% | 81.6% |
| 每股收益（稀释后） | $0.51 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $183.1M | $117.7M | ||
| Q3 25 | $191.8M | $120.2M | ||
| Q2 25 | $174.4M | $139.3M | ||
| Q1 25 | $170.5M | $129.4M | ||
| Q4 24 | $186.5M | $145.6M | ||
| Q3 24 | $191.2M | $136.9M | ||
| Q2 24 | $182.4M | $148.2M | ||
| Q1 24 | $171.8M | $151.3M |
| Q4 25 | $24.4M | $-12.7M | ||
| Q3 25 | $17.4M | $-2.4M | ||
| Q2 25 | $31.0M | $-73.3M | ||
| Q1 25 | $25.3M | $-44.1M | ||
| Q4 24 | $38.0M | $-68.7M | ||
| Q3 24 | $40.4M | $-5.7M | ||
| Q2 24 | $37.9M | $10.5M | ||
| Q1 24 | $43.2M | $2.5M |
| Q4 25 | 46.8% | 37.1% | ||
| Q3 25 | 51.4% | 39.5% | ||
| Q2 25 | 49.6% | 40.2% | ||
| Q1 25 | 50.0% | 35.1% | ||
| Q4 24 | 46.5% | 38.5% | ||
| Q3 24 | 53.3% | 36.5% | ||
| Q2 24 | 52.2% | 40.2% | ||
| Q1 24 | 52.4% | 37.0% |
| Q4 25 | 19.4% | -10.3% | ||
| Q3 25 | 13.2% | -1.7% | ||
| Q2 25 | 24.2% | -47.0% | ||
| Q1 25 | 21.9% | -38.4% | ||
| Q4 24 | 24.2% | -52.7% | ||
| Q3 24 | 29.8% | -3.5% | ||
| Q2 24 | 30.3% | 7.6% | ||
| Q1 24 | 27.9% | 2.8% |
| Q4 25 | 13.3% | -10.8% | ||
| Q3 25 | 9.0% | -2.0% | ||
| Q2 25 | 17.8% | -52.6% | ||
| Q1 25 | 14.8% | -34.0% | ||
| Q4 24 | 20.4% | -47.2% | ||
| Q3 24 | 21.1% | -4.2% | ||
| Q2 24 | 20.8% | 7.1% | ||
| Q1 24 | 25.1% | 1.7% |
| Q4 25 | $0.51 | $-0.38 | ||
| Q3 25 | $0.37 | $-0.07 | ||
| Q2 25 | $0.64 | $-2.21 | ||
| Q1 25 | $0.51 | $-1.34 | ||
| Q4 24 | $0.74 | $-2.08 | ||
| Q3 24 | $0.78 | $-0.17 | ||
| Q2 24 | $0.73 | $0.31 | ||
| Q1 24 | $0.81 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $89.8M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $194.6M |
| 总资产 | $1.6B | $289.3M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
| Q4 25 | $282.8M | $89.8M | ||
| Q3 25 | $276.2M | $77.5M | ||
| Q2 25 | $231.8M | $86.1M | ||
| Q1 25 | $236.9M | $72.5M | ||
| Q4 24 | $221.6M | $78.2M | ||
| Q3 24 | $250.5M | $89.6M | ||
| Q2 24 | $217.8M | $108.9M | ||
| Q1 24 | $289.6M | $113.8M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $194.6M | ||
| Q3 25 | $776.7M | $206.4M | ||
| Q2 25 | $757.5M | $207.1M | ||
| Q1 25 | $751.3M | $277.8M | ||
| Q4 24 | $732.3M | $325.7M | ||
| Q3 24 | $727.7M | $407.2M | ||
| Q2 24 | $713.3M | $418.8M | ||
| Q1 24 | $672.4M | $414.9M |
| Q4 25 | $1.6B | $289.3M | ||
| Q3 25 | $1.7B | $287.2M | ||
| Q2 25 | $1.6B | $304.7M | ||
| Q1 25 | $1.6B | $375.6M | ||
| Q4 24 | $1.6B | $424.9M | ||
| Q3 24 | $1.5B | $512.9M | ||
| Q2 24 | $1.5B | $510.9M | ||
| Q1 24 | $1.6B | $523.2M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $15.6M |
| 自由现金流率自由现金流/营收 | 13.4% | 13.2% |
| 资本支出强度资本支出/营收 | 4.5% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $24.3M |
8季度趋势，按日历期对齐
| Q4 25 | $32.9M | $15.9M | ||
| Q3 25 | $52.6M | $-7.8M | ||
| Q2 25 | $35.6M | $16.8M | ||
| Q1 25 | $35.1M | $659.0K | ||
| Q4 24 | $29.0M | $1.8M | ||
| Q3 24 | $60.0M | $-309.0K | ||
| Q2 24 | $69.1M | $3.2M | ||
| Q1 24 | $55.3M | $20.5M |
| Q4 25 | $24.6M | $15.6M | ||
| Q3 25 | $47.2M | $-8.0M | ||
| Q2 25 | $25.0M | $16.5M | ||
| Q1 25 | $24.4M | $238.0K | ||
| Q4 24 | $16.6M | $61.0K | ||
| Q3 24 | $46.2M | $-575.0K | ||
| Q2 24 | $63.1M | $3.0M | ||
| Q1 24 | $46.5M | $20.4M |
| Q4 25 | 13.4% | 13.2% | ||
| Q3 25 | 24.6% | -6.6% | ||
| Q2 25 | 14.3% | 11.8% | ||
| Q1 25 | 14.3% | 0.2% | ||
| Q4 24 | 8.9% | 0.0% | ||
| Q3 24 | 24.1% | -0.4% | ||
| Q2 24 | 34.6% | 2.1% | ||
| Q1 24 | 27.1% | 13.5% |
| Q4 25 | 4.5% | 0.3% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.3% | ||
| Q4 24 | 6.7% | 1.2% | ||
| Q3 24 | 7.2% | 0.2% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.1% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 0.30× | ||
| Q1 24 | 1.28× | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
